But oropharyngeal squamous cell carcinoma presents in the soft palate, tonsillar region, or base of tongue. Early cases of oropharyngeal squamous cell carcinoma are generally asymptomatic.

They analyzed 295 patients with newly diagnosed stage cT2-4N0-2M0 squamous cell carcinoma of the oropharynx, larynx, or hypopharynx who were randomly assigned in a 2:1 ratio to receive definitive ...

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn ... the drug is currently being investigated in six clinical trials in disease types including oropharyngeal cancer, ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

The American Cancer Society (ACS) estimates that 59,660 people will receive an oral cavity cancer or oropharyngeal cancer ... be a possible symptom of squamous cell carcinoma.

Presentation title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial ...

Dr. Chris Holsinger shares the new guideline from ASCO on transoral robotic surgery (TORS) for patients with oropharyngeal squamous cell carcinoma. He reviews the evidence-based recommendations on ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...